Andy Zeitlin
Celgene
6 Papers
147 Citations
Andy Zeitlin is an academic researcher from Celgene. The author has contributed to research in topics: Placenta cord banking & Cell. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table.
Ornella Parolini,Francesco Alviano,Irene Bergwerf,Diana Boraschi,Cosimo De Bari,Peter De Waele,Massimo Dominici,Marco Evangelista,Werner Falk,Simone Hennerbichler,David C. Hess,Giacomo Lanzoni,Bing Liu,Fabio Marongiu,Colin McGuckin,Stefan Mohr,Maria Luisa Nolli,Racheli Ofir,Peter Ponsaerts,Luca Romagnoli,Abraham Solomon,Maddalena Soncini,Stephen C. Strom,Daniel Surbek,Sankar Venkatachalam,Sankar Venkatachalam,Susanne Wolbank,Steffen M. Zeisberger,Andy Zeitlin,Andreas H. Zisch,Cesar V. Borlongan +30 more
TL;DR: The international workshop held in Brescia, Italy, in March 2009 aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases.
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Xin Li,Wen Ling,Angela Pennisi,Yuping Wang,Sharmin Khan,Mohammad A. Heidaran,Ajai Pal,Xiaokui Zhang,Shuyang He,Andy Zeitlin,Stewart Abbot,Herbert Faleck,Robert J. Hariri,John D. Shaughnessy,Frits van Rhee,Bijay Nair,Bart Barlogie,Joshua Epstein,Shmuel Yaccoby +18 more
TL;DR: It is suggested that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC chemotherapy is a promising therapeutic approach for myelomatous osteolysis.
Patent
Cell composition and methods of making the same
Andy Zeitlin,Gregory Russotti,Shuyang He,Ajai Pal,Hong J. Chen,Thomas Brieva,Ryan Shorr,Brian Murphy +7 more
- 20 Aug 2009
TL;DR: In this article, improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby are presented, along with improved cell formulations and compositions.
48
Patent
Improved cell composition and methods of making the same
Andy Zeitlin,Gregory Russotti,Shuyang He,Ajai Pal,Hong J. Chen,Thomas Brieva,Ryan Shorr,Brian Murphy +7 more
- 20 Aug 2009
TL;DR: In this paper, improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby are presented, along with improved cell formulations and compositions.
18
Patent
Improved cell compositions, and methods of making the same
ザイトリン，アンディ,Andy Zeitlin,ルソッティ，グレゴリー,Gregory Russotti,ヒ−，シューヤン,Shuyang He,パル，アジャイ,Ajai Pal,チェン，ホン，ジェイ．,Hong J. Chen,ブリエバ，トーマス,Thomas Brieva,ショアー，リアン,Ryan Shorr,マーフィー ブライアン,Brian Murphy +15 more
- 03 Jul 2015
TL;DR: In this paper, the authors proposed a composition comprising placental stem cells such as CD34, CD10, CD200, CD105, OCT-4, CD90, CD45, CD80, CD86, CD29, CD38, CD44, CD54, SH3or SH4, dextran, human serum albumin, and dimethylsulfoxide (DMSO) as a cryoprotective agent.